Pietro Belloni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Pietro Belloni has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Margherita Silan
Department of Statistical Sciences, University of Padua , Via C. Battisti 241 - 35121, Padua
2 shared publications - Andrea Sottosanti
University of Padova
1 shared publication - Annunziata Lapolla
Universita Degli Studi di Padova Padua Italy
1 shared publication - Corin Cozzi
A.O. G. Salvini, Rho
1 shared publication D. Toniolo
A.O. G. Salvini, Rho
1 shared publication- Elisa Cisotto
Università Cattolica del Sacro Cuore
1 shared publication
Latest Publications
- Open Access
- 2 November 2026
- Published by Oxford University Press (OUP) in Journal of the Royal Statistical Society Series A: Statistics in Society
Measuring frailty in older adults: an indicator based on a super-classifier
Identifying frail older adults in an ageing population is essential for improving healthcare services. This study proposes a composite indicator to assess individual frailty levels using administrative healthcare data. Given the complex and multidimensional nature of frailty, a multi-outcome approach is adopted. Following an extensive literature review, a set of adverse health events is selected as proxies for frailty. These events were modelled using logistic classifiers, with frailty determinants (associated to adverse health events, selected using a gradient tree boosting) serving as covariates. The sensitivity and specificity of each classifier is used to compose their combined likelihood. From this, we derive an indicator capable of quantifying frailty across the population. The indicator shows robust performance across multiple outcomes and over time. Its primary innovation lies in allowing the use of diverse and outcome-specific sets of frailty determinants without any structural constraint. Overall, we offer an effective tool for quantifying frailty among older adults, potentially supporting health authorities in the prevention of frailty-related adverse events.
- 2 November 2026
- Published by Oxford University Press (OUP) in Journal of the Royal Statistical Society Series A: Statistics in Society
Open AccessMeasuring frailty in older adults: an indicator based on a super-classifier
Identifying frail older adults in an ageing population is essential for improving healthcare services. This study proposes a composite indicator to assess individual frailty levels using administrative healthcare data. Given the complex and multidimensional nature of frailty, a multi-outcome approach is adopted. Following an extensive literature review, a set of adverse health events is selected as proxies for frailty. These events were modelled using logistic classifiers, with frailty determinants (associated to adverse health events, selected using a gradient tree boosting) serving as covariates. The sensitivity and specificity of each classifier is used to compose their combined likelihood. From this, we derive an indicator capable of quantifying frailty across the population. The indicator shows robust performance across multiple outcomes and over time. Its primary innovation lies in allowing the use of diverse and outcome-specific sets of frailty determinants without any structural constraint. Overall, we offer an effective tool for quantifying frailty among older adults, potentially supporting health authorities in the prevention of frailty-related adverse events.
- Open Access
- 5 March 2026
- Published by Elsevier in Social Science & Medicine
- Vol. 398, 119154
Mapping social health and dementia risk: A register-based study of older adults in Finland
- 5 March 2026
- Published by Elsevier in Social Science & Medicine
- Vol. 398, 119154
Open AccessMapping social health and dementia risk: A register-based study of older adults in Finland
- Open Access
- 31 December 2024
- Published by Oxford University Press (OUP) in Biostatistics
- Vol. 26 (1)
Bayesian mapping of mortality clusters
Summary: Disease mapping analyses the distribution of several disease outcomes within a territory. Primary goals include identifying areas with unexpected changes in mortality rates, studying the relation among multiple diseases, and dividing the analysed territory into clusters based on the observed levels of disease incidence or mortality. In this work, we focus on detecting spatial mortality clusters, that occur when neighbouring areas within a territory exhibit similar mortality levels due to one or more diseases. When multiple causes of death are examined together, it is relevant to identify not only the spatial boundaries of the clusters but also the diseases that lead to their formation. However, existing methods in literature struggle to address this dual problem effectively and simultaneously. To overcome these limitations, we introduce perla, a multivariate Bayesian model that clusters areas in a territory according to the observed mortality rates of multiple causes of death, also exploiting the information of external covariates. Our model incorporates the spatial structure of data directly into the clustering probabilities by leveraging the stick-breaking formulation of the multinomial distribution. Additionally, it exploits suitable global-local shrinkage priors to ensure that the detection of clusters depends on diseases showing concrete increases or decreases in mortality levels, while excluding uninformative diseases. We propose a Markov chain Monte Carlo algorithm for posterior inference that consists of closed-form Gibbs sampling moves for nearly every model parameter, without requiring complex tuning operations. This work is primarily motivated by a case study on the territory of a local unit within the Italian public healthcare system, known as ULSS6 Euganea. To demonstrate the flexibility and effectiveness of our methodology, we also validate perla with a series of simulation experiments and an extensive case study on mortality levels in U.S. counties.
- 31 December 2024
- Published by Oxford University Press (OUP) in Biostatistics
- Vol. 26 (1)
Open AccessBayesian mapping of mortality clusters
Summary: Disease mapping analyses the distribution of several disease outcomes within a territory. Primary goals include identifying areas with unexpected changes in mortality rates, studying the relation among multiple diseases, and dividing the analysed territory into clusters based on the observed levels of disease incidence or mortality. In this work, we focus on detecting spatial mortality clusters, that occur when neighbouring areas within a territory exhibit similar mortality levels due to one or more diseases. When multiple causes of death are examined together, it is relevant to identify not only the spatial boundaries of the clusters but also the diseases that lead to their formation. However, existing methods in literature struggle to address this dual problem effectively and simultaneously. To overcome these limitations, we introduce perla, a multivariate Bayesian model that clusters areas in a territory according to the observed mortality rates of multiple causes of death, also exploiting the information of external covariates. Our model incorporates the spatial structure of data directly into the clustering probabilities by leveraging the stick-breaking formulation of the multinomial distribution. Additionally, it exploits suitable global-local shrinkage priors to ensure that the detection of clusters depends on diseases showing concrete increases or decreases in mortality levels, while excluding uninformative diseases. We propose a Markov chain Monte Carlo algorithm for posterior inference that consists of closed-form Gibbs sampling moves for nearly every model parameter, without requiring complex tuning operations. This work is primarily motivated by a case study on the territory of a local unit within the Italian public healthcare system, known as ULSS6 Euganea. To demonstrate the flexibility and effectiveness of our methodology, we also validate perla with a series of simulation experiments and an extensive case study on mortality levels in U.S. counties.
- Open Access
- 11 April 2022
- Published by Wiley in International Journal of Endocrinology
- Vol. 2022, 1-6
Can the First Fasting Plasma Glucose Test in Pregnancy Predict Subsequent Gestational Complications?
Objective. To determine the best cut-off level of pregnant women’s first fasting plasma glucose (FFPG) test results for the prediction of subsequent onset of gestational diabetes mellitus (GDM) and to examine the association between FFPG and maternal and neonatal outcomes in a large Caucasian population. Methods. 1437 medical records of women with singleton pregnancies followed up between 2015 and 2018 were retrospectively analyzed. Data on FFPG tested in the first trimester and 75 g oral glucose tolerance test (OGTT) findings performed according to IADPSG criteria and Italian guidelines were collected and evaluated. The women’s clinical and metabolic characteristics (age, prepregnancy body mass index (BMI), previous pregnancies complicated by GDM, timing of delivery, and gestational hypertension) were also recorded. The fetal variables considered were being large for gestational age (LGA) or small for gestational age (SGA), macrosomia, and hypoglycemia. Results. Among the 1437 pregnant women studied, 684 had a normal glucose tolerance (NGT) and 753 developed GDM. In a univariate analysis FFPG ≥92 mg/dl predicts the risk of GDM with an OR = 2.36 (95% CI 1.930–3.186; ). In multivariate analysis, after adjusting for principal risk factors of GDM (BMI, previous GDM, age >35 years, family history of diabetes) FFPG ≥92 mg/dl was associated with the risk of GDM (OR = 1.92; 95% CI 1.488–2.492; ). In univariate analysis, FFPG ≥92 mg/dl predict the risk of insulin therapy in GDM women with a OR = 1.88 (95% CI 1.230–2.066; ). As regards LGA, in a multivariate analysis, after adjusting for BMI, FFPG ≥92 mg/dl was associated with the risk of LGA only in NGT women (OR = 2.34; 95% CI 1.173–4.574; ), but not in GDM women. FFPG was not associated with other maternal or neonatal outcomes. Conclusions. FFPG ≥92 mg/dl is related to GDM diagnosis and to the need of insulin therapy if GDM is diagnosed. An early diagnosis and a prompt start of insulin therapy are essential to prevent maternal and fetal complications.
- 11 April 2022
- Published by Wiley in International Journal of Endocrinology
- Vol. 2022, 1-6
Open AccessCan the First Fasting Plasma Glucose Test in Pregnancy Predict Subsequent Gestational Complications?
Objective. To determine the best cut-off level of pregnant women’s first fasting plasma glucose (FFPG) test results for the prediction of subsequent onset of gestational diabetes mellitus (GDM) and to examine the association between FFPG and maternal and neonatal outcomes in a large Caucasian population. Methods. 1437 medical records of women with singleton pregnancies followed up between 2015 and 2018 were retrospectively analyzed. Data on FFPG tested in the first trimester and 75 g oral glucose tolerance test (OGTT) findings performed according to IADPSG criteria and Italian guidelines were collected and evaluated. The women’s clinical and metabolic characteristics (age, prepregnancy body mass index (BMI), previous pregnancies complicated by GDM, timing of delivery, and gestational hypertension) were also recorded. The fetal variables considered were being large for gestational age (LGA) or small for gestational age (SGA), macrosomia, and hypoglycemia. Results. Among the 1437 pregnant women studied, 684 had a normal glucose tolerance (NGT) and 753 developed GDM. In a univariate analysis FFPG ≥92 mg/dl predicts the risk of GDM with an OR = 2.36 (95% CI 1.930–3.186; ). In multivariate analysis, after adjusting for principal risk factors of GDM (BMI, previous GDM, age >35 years, family history of diabetes) FFPG ≥92 mg/dl was associated with the risk of GDM (OR = 1.92; 95% CI 1.488–2.492; ). In univariate analysis, FFPG ≥92 mg/dl predict the risk of insulin therapy in GDM women with a OR = 1.88 (95% CI 1.230–2.066; ). As regards LGA, in a multivariate analysis, after adjusting for BMI, FFPG ≥92 mg/dl was associated with the risk of LGA only in NGT women (OR = 2.34; 95% CI 1.173–4.574; ), but not in GDM women. FFPG was not associated with other maternal or neonatal outcomes. Conclusions. FFPG ≥92 mg/dl is related to GDM diagnosis and to the need of insulin therapy if GDM is diagnosed. An early diagnosis and a prompt start of insulin therapy are essential to prevent maternal and fetal complications.
- 26 September 2015
- Published by Elsevier in Annals of Oncology
- Vol. 26 (suppl_6) , vi117
GelX Oral Gel and GelX Oral Spray (GOG&GOS) pain relief for oral mucositis
Oral Mucositis (OM) is a painful condition affecting the mucosa of the mouth and throat.OM refers specifically to toxicity associated with chemotherapy and radiation therapy for cancer. Approximately 40% of pz receiving chemotherapy as part of their cancer treatment will develop some degree of Mucositis. The process of oral mucositis involves not only the epithelium, but also includes multiple cellular processes of the lamina propria and sub-mucosa. Inflammation is a complex biological event; a loss of mineral homeostasis contributes to the destructive effects of this process. Current treatment for OM is largely palliative and no adequate treatment with conclusive evidence exists.
- 26 September 2015
- Published by Elsevier in Annals of Oncology
- Vol. 26 (suppl_6) , vi117
GelX Oral Gel and GelX Oral Spray (GOG&GOS) pain relief for oral mucositis
Oral Mucositis (OM) is a painful condition affecting the mucosa of the mouth and throat.OM refers specifically to toxicity associated with chemotherapy and radiation therapy for cancer. Approximately 40% of pz receiving chemotherapy as part of their cancer treatment will develop some degree of Mucositis. The process of oral mucositis involves not only the epithelium, but also includes multiple cellular processes of the lamina propria and sub-mucosa. Inflammation is a complex biological event; a loss of mineral homeostasis contributes to the destructive effects of this process. Current treatment for OM is largely palliative and no adequate treatment with conclusive evidence exists.